Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nina Zolotarjova

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
Multi-component immunoaffinity subtraction and reversed-phase chromatography of human serumJames Martosella, Nina Zolotarjova
Journal of Chromatography. A|December 25, 2007
Combination of affinity depletion of abundant proteins and reversed-phase fractionation in proteomic analysis of human plasma/serumNina Zolotarjova, Peter Mrozinski, Haiying Chen, et al.
Journal of Proteome Research|October 11, 2005
Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteinsJames Martosella, Nina Zolotarjova, Hongbin Liu, et al.
Proteomics|July 30, 2005
Differences among techniques for high-abundant protein depletionNina Zolotarjova, James Martosella, Gordon Nicol, et al.
Journal of Proteome Research|June 3, 2006
High recovery HPLC separation of lipid rafts for membrane proteome analysisJames Martosella, Nina Zolotarjova, Hongbin Liu, et al.
Electrophoresis|July 27, 2004
Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometryGiuseppina Maccarrone, Dale Milfay, Isabel Birg, et al.
Blood Neoplasia|April 20, 2026
Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosisHamza Celik, Brittney Wass, Nina Zolotarjova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesMatthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
Cancer Discovery|March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 InhibitorHolly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
Multi-component immunoaffinity subtraction and reversed-phase chromatography of human serumJames Martosella, Nina Zolotarjova
Journal of Chromatography. A|December 25, 2007
Combination of affinity depletion of abundant proteins and reversed-phase fractionation in proteomic analysis of human plasma/serumNina Zolotarjova, Peter Mrozinski, Haiying Chen, et al.
Journal of Proteome Research|October 11, 2005
Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteinsJames Martosella, Nina Zolotarjova, Hongbin Liu, et al.
Proteomics|July 30, 2005
Differences among techniques for high-abundant protein depletionNina Zolotarjova, James Martosella, Gordon Nicol, et al.
Journal of Proteome Research|June 3, 2006
High recovery HPLC separation of lipid rafts for membrane proteome analysisJames Martosella, Nina Zolotarjova, Hongbin Liu, et al.
Electrophoresis|July 27, 2004
Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometryGiuseppina Maccarrone, Dale Milfay, Isabel Birg, et al.
Blood Neoplasia|April 20, 2026
Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosisHamza Celik, Brittney Wass, Nina Zolotarjova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesMatthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
Cancer Discovery|March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 InhibitorHolly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Pageof 1